Mim8 for prophylaxis of haemophilia A


featured image

Mim8 (NNC0365-3769) is in clinical development for haemophilia A with or without inhibitors. Haemophilia is a rare condition that affects the blood's ability to clot. It is usually inherited. An inhibitor is a type of antibody that prevents factor replacement treatment from working.

Interventions: NNC0365-3769
Indications: Haemophilia A
Therapeutic Areas: Haematology
Year: 2023

Mim8 (NNC0365-3769) is in clinical development for haemophilia A with or without inhibitors.
Haemophilia is a rare condition that affects the blood's ability to clot. It is usually inherited. An
inhibitor is a type of antibody that prevents factor replacement treatment from working.
Normally, when you cut yourself, substances in your blood known as clotting factors mix with
blood cells called platelets to make your blood sticky and form a clot. This makes the bleeding
stop eventually. Haemophilia A is a bleeding disorder caused by missing or defective factor VIII
(FVIII), a blood clotting protein. As a result, people with haemophilia A may suffer from
spontaneous or traumatic bleeds due to the missing or defective FVIII. Despite the availability of
several medicinal products to prevent bleeding in haemophilia A, there are still unmet needs such
as frequent injection, inability to prevent micro-bleeds, or traumatic bleedings.